Infectious disease specialist Poolbeg Pharma is planning to list on New York’s Nasdaq in the coming months, according to its chairman Cathal Friel.
The company was last week spun out by its parent, pharmaceutical services firm Open Orphan, and it announced to the market that it was preparing for a £25m (€29m) initial public offering (IPO) on London’s AIM index.
Friel, who leads life sciences focused corporate finance house Raglan Capital, which successfully brought Open Orphan to the market two years ago, has since told the Sunday Independent that Poolbeg is planning a dual listing in New York and London.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
